/CNTX
CNTX Stock - Context Therapeutics Inc.
Healthcare|BiotechnologyNASDAQ
$1.27+10.43%
+$0.12 (+10.43%) • Dec 19
78
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.98
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.42
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+307.1%upside
Target: $5.17
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for CNTX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.26 – $1.28
TARGET (TP)$5.17
STOP LOSS$1.17
RISK/REWARD1:39.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.94
52W High$1.55
52W Low$0.49
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-29,923,900 | $-25,072,616 | $-15,381,203 | $-10,525,819 | $-2,572,000 |
| Net Income | $-26,725,104 | $-23,964,211 | $-14,835,939 | $-10,456,870 | $6.64M |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-0.46 | $-1.50 | $-0.93 | $-3.69 | $0.61 |
Company Overview
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers. The company is also developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for gynaecologic cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
4
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
4 Bullish0 Neutral/Bearish
Price Targets
$6
Average Target
↑ 342.9% Upside
Now
$4
Low
$6
Average
$9
High
Based on 4 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| September 18th 2025 | Guggenheim | Initiation | Buy | $5 |
| April 21st 2025 | William Blair | Initiation | Outperform | - |
| January 8th 2025 | JMP Securities | Initiation | Mkt Outperform | $4 |
| November 25th 2024 | D. Boral Capital | Initiation | Buy | $9 |
| May 16th 2024 | Piper Sandler | Initiation | Overweight | $4.5 |
Earnings History & Surprises
CNTXBeat Rate
38%
Last 16 quarters
Avg Surprise
-14.6%
EPS vs Estimate
Beats / Misses
6/8
2 met exactly
Latest EPS
$-0.10
Q4 2025
EPS Surprise History
Q1 24
-20.0%
$-0.42vs$-0.35
Q2 24
+39.5%
$-0.23vs$-0.38
Q3 24
+50.0%
$-0.04vs$-0.08
Q4 24
-100.0%
$-0.22vs$-0.11
Q1 25
+20.0%
$-0.04vs$-0.05
Q2 25
0.0%
$-0.05vs$-0.05
Q3 25
-50.0%
$-0.09vs$-0.06
Q4 25
-11.1%
$-0.10vs$-0.09
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 19, 2026 | $-0.10 | — | — | — |
Q1 2026 | Mar 19, 2026 | $-0.10 | — | — | — |
Q4 2025 | Nov 5, 2025 | $-0.09 | $-0.10 | -11.1% | ✗ MISS |
Q3 2025 | Aug 6, 2025 | $-0.06 | $-0.09 | -50.0% | ✗ MISS |
Q2 2025 | May 7, 2025 | $-0.05 | $-0.05 | 0.0% | = MET |
Q1 2025 | Mar 20, 2025 | $-0.05 | $-0.04 | +20.0% | ✓ BEAT |
Q4 2024 | Nov 6, 2024 | $-0.11 | $-0.22 | -100.0% | ✗ MISS |
Q3 2024 | Aug 7, 2024 | $-0.08 | $-0.04 | +50.0% | ✓ BEAT |
Q2 2024 | May 8, 2024 | $-0.38 | $-0.23 | +39.5% | ✓ BEAT |
Q1 2024 | Mar 21, 2024 | $-0.35 | $-0.42 | -20.0% | ✗ MISS |
Q4 2023 | Nov 9, 2023 | $-0.30 | $-0.37 | -23.3% | ✗ MISS |
Q3 2023 | Aug 9, 2023 | $-0.20 | $-0.31 | -55.0% | ✗ MISS |
Q2 2023 | May 10, 2023 | $-0.19 | $-0.40 | -110.5% | ✗ MISS |
Q1 2023 | Mar 22, 2023 | $-0.30 | $-0.22 | +26.7% | ✓ BEAT |
Q4 2022 | Nov 9, 2022 | $-0.25 | $-0.24 | +4.0% | ✓ BEAT |
Q3 2022 | Aug 11, 2022 | $-0.25 | $-0.25 | 0.0% | = MET |
Q2 2022 | May 11, 2022 | $-0.24 | $-0.22 | +8.3% | ✓ BEAT |
Q1 2022 | Mar 24, 2022 | $-0.27 | $-0.30 | -12.2% | ✗ MISS |
Q4 2021 | Dec 2, 2021 | — | $-4.00 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.73 | — | — |
Latest News
Context Therapeutics Showcases CT-95 And CT-202 At 2025 SITC; CT-95 Advancing In Phase 1 With Favorable Safety, Initial Data Mid-2026; CT-202 Targeting First-In-Human In Q2 2026
📈 PositiveBenzinga•Nov 7, 2025, 12:42 PM
D. Boral Capital Maintains Buy on Context Therapeutics, Maintains $9 Price Target
📈 PositiveBenzinga•Nov 6, 2025, 01:22 PM
HC Wainwright & Co. Maintains Buy on Context Therapeutics, Raises Price Target to $5
📈 PositiveBenzinga•Nov 6, 2025, 11:52 AM
Context Therapeutics Q3 EPS $(0.10) Misses $(0.09) Estimate
📉 NegativeBenzinga•Nov 5, 2025, 10:02 PM
Context Therapeutics Amends Sales Agreement, May Offer & Sell From Time To Time Common Stock Of Up To $75M
📈 PositiveBenzinga•Oct 24, 2025, 08:11 PM
D. Boral Capital Maintains Buy on Context Therapeutics, Maintains $9 Price Target
📈 PositiveBenzinga•Oct 16, 2025, 12:40 PM
Context Therapeutics To Present Cancer Immunotherapy Data At SITC 2025
📈 PositiveBenzinga•Oct 6, 2025, 11:38 AM
Cantor Fitzgerald Initiates Coverage On Context Therapeutics with Overweight Rating
📈 PositiveBenzinga•Oct 2, 2025, 12:40 PM
Guggenheim Initiates Coverage On Context Therapeutics with Buy Rating, Announces Price Target of $5
📈 PositiveBenzinga•Sep 18, 2025, 01:02 PM
Frequently Asked Questions about CNTX
What is CNTX's current stock price?
Context Therapeutics Inc. (CNTX) is currently trading at $1.27 per share. The stock has moved +10.43% today.
What is the analyst price target for CNTX?
The average analyst price target for CNTX is $5.17, based on 1 analyst.
What sector is Context Therapeutics Inc. in?
Context Therapeutics Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is CNTX's market cap?
Context Therapeutics Inc. has a market capitalization of $0.12 billion, making it a small-cap company.
Does CNTX pay dividends?
No, Context Therapeutics Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorCLNN
Clene Inc.
$6.68
Mkt Cap: $0.1B
CNTB
Connect Biopharma Holdings Limited
$2.27
Mkt Cap: $0.1B
IFRX
InflaRx N.V.
$1.11
Mkt Cap: $0.1B
IMA
ImageneBio Inc
$6.18
Mkt Cap: $0.1B
KLRS
Kalaris Therapeutics Inc
$9.13
Mkt Cap: $0.2B
MGNX
MacroGenics, Inc.
$1.50
Mkt Cap: $0.1B
ORMP
Oramed Pharmaceuticals Inc.
$2.93
Mkt Cap: $0.1B
OVID
Ovid Therapeutics Inc.
$1.47
Mkt Cap: $0.1B
STTK
Shattuck Labs, Inc.
$3.15
Mkt Cap: $0.2B
WHWK
Whitehawk Therapeutics Inc
$2.56
Mkt Cap: $0.1B
Explore stocks similar to CNTX for comparison